MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology director Stan Smith reported indirect ownership changes in the company’s common stock. On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with him, purchased 2,700 shares of MAIA common stock at $3.6884 per share, bringing that trust’s reported indirect holdings to 1,424,178 shares.
On May 1, 2024, 20,000 shares previously held in the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, increasing that trust’s reported indirect holdings to 1,444,178 shares. Three additional IL Uniform Transfers to Minors Act accounts for family members each hold 4,580 shares, where Smith reports indirect beneficial ownership but disclaims it except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. reported that a company director received a new stock option grant. On 12/31/2025, the director was granted options to purchase 24,060 shares of MAIA Biotechnology common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of 12/31/2035. Following this grant, the director holds 24,060 derivative securities directly.
MAIA Biotechnology director option grant reported
MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The options cover 29,216 shares of common stock at an exercise price of $1.53 per share and vest 100% on the grant date, meaning they are exercisable beginning 12/31/2025.
The options have an expiration date of 12/31/2035. Following this grant, 29,216 derivative securities are shown as beneficially owned indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director reports new stock option grant
A MAIA Biotechnology, Inc. director filed a Form 4 disclosing a grant of stock options on December 31, 2025 under the company’s 2021 Equity Incentive Plan. The grant covers 25,206 stock options, each giving the right to buy one share of MAIA common stock at an exercise price of $1.53 per share. These options vest 100% on the grant date and are exercisable beginning that same day, with an expiration date of December 31, 2035. Following this grant, the reporting person holds 25,206 derivative securities directly, all in the form of these options.
MAIA Biotechnology, Inc. reported that director Louie Ngar Yee received a grant of stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The grant covers 29,789 options to buy common stock at an exercise price of $1.53 per share.
The options vest 100% on the grant date and are exercisable beginning 12/31/2025, giving the director the right to purchase MAIA common shares at this fixed price. These options expire on 12/31/2035 if not exercised, so they represent a long-term equity incentive tied to the company’s future performance.
MAIA Biotechnology, Inc. reported an equity award to one of its directors. On December 31, 2025, the director received stock options to purchase 24,060 shares of MAIA common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. These options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of December 31, 2035. Following this grant, the director beneficially owns 24,060 derivative securities directly in the form of these options.
MAIA Biotechnology, Inc. reported an equity award to one of its directors on a Form 4 insider transaction report. On December 31, 2025, the director received 24,633 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. These options have an exercise price of $1.53 per share, vest 100% on the grant date, and are exercisable beginning December 31, 2025, through December 31, 2035. Following this grant, the director beneficially owns 24,633 derivative securities in the form of these options, held directly.
MAIA Biotechnology director Stan V. Smith reported buying additional shares and options in the company. On December 22, 2025, he purchased 57,189 shares of MAIA common stock at $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. After this transaction, he beneficially owns 1,421,478 shares indirectly through The Stan V. Smith Trust Dated 1993, plus additional indirect holdings of 4,580 shares in each of three separate family trusts.
He also acquired 57,189 stock options (described as warrants deemed options) with an exercise price of $1.36 per share. These options become exercisable on the six-month anniversary of the issuance date, June 22, 2026, and expire three years after the initial issuance date, on December 22, 2028. The filing notes that certain family-trust shares are held for relatives and that he disclaims beneficial ownership of those except to the extent of any pecuniary interest.
MAIA Biotechnology director reports stock and option purchases. A company director filed details of a recent transaction in MAIA Biotechnology, Inc. common stock. On December 22, 2025, the director purchased 40,849 shares of common stock at a price of $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. Following this transaction, the director beneficially owns 151,873 shares of MAIA common stock directly.
The director also acquired 40,849 stock options (treated as warrants under the same purchase agreement and plan) with an exercise price of $1.36 per share. These options become exercisable on June 22, 2026, which is six months after the issuance date, and are scheduled to expire on December 22, 2028.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported an insider purchase of common stock and related stock options. On 12/22/2025, the director acquired 81,699 shares of common stock at $1.224 per share pursuant to a Securities Purchase Agreement, bringing total directly held common shares to 1,248,888.
On the same date, the director also acquired stock options on 81,699 shares with an exercise price of $1.36 per share. These options, deemed options under the company’s 2021 Equity Incentive Plan, become exercisable on 06/22/2026 and expire on 12/22/2028. Following these transactions, the director beneficially owns 81,699 derivative securities in addition to the common stock holdings.